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doi:10.1016/j.ejvs.2009.12.024Abstract Objective: The Japanese Committee for Stentgraft Management (JACSM) was
established with the aim of ensuring the safe and proper reach of commercial stent grafts
following their regulatory approval. This study examines the validity of the practice standards
developed by JACSM.
Methods: JACSM comprises 10 associations related to endovascular treatment. Based on the
practice standards developed by JACSM, the status of practising institutions, practising
surgeons, supervising surgeons and the results of follow-up surveys were analysed.
Results: In the 2.5 years following the establishment of JACSM, 298 institutions have fulfilled
the practice standards. The number of practising surgeons reached 493, and the number of
supervising surgeons reached 177. There were 3089 registered cases up to June 2009. The
present study analysed 1570 cases registered in the 2 years from July 2006 to June 2008.
The hospital mortality rate was low (0.4%) in the follow-up surveys.
Conclusions: Early results following the introduction of stent grafts were generally good. The
procedure spread safely without the learning curve seen in the initial stages following intro-
duction of new medical materials, indicating that the practice standards were appropriate.
ª 2010 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.eting 3e6 September, 2009.
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Endovascular aortic aneurysm repair (EVAR), an endovas-
cular treatment, is a part of the treatment strategy for
abdominal aortic aneurysms (AAAs). Since its introduction,
various modifications to and developments of the device
system have been made, and it has extended worldwide as
a common treatment. According to the National Inpatients
Sample in the United States, EVAR accounted for 50% ofd by Elsevier Ltd. All rights reserved.
Table 1 Ten societies form the JACSM.
Japanese College of Angiology (JCA)
Japanese Circulation Society (JCS)
Japanese Association of Cardiovascular Intervention and
Therapeutics (CVIT)
Japanese Society of Interventional Radiology (JSIR)
Japanese Society for Vascular Surgery (JSVS)
Japanese Society of Cardiovascular Surgery (JSCVS)
Japanese Society of Phlebology (JSP)
Japanese Society of Endovascular Intervention (JSEI)
Japanese Society for Artificial Organe (JSAO)
Japanese Association for Thoracic Surgery (JATS)
S6 Y. Obitsu et al.elective AAA surgeries in 2004.1 In Japan, where EVAR
came into use later, the Zenith AAA endovascular graft
(Cook Medical, IN, USA), a commercial stent graft for use
with the abdominal aorta, finally received regulatory
approval in July 2006. To date, three systems, the Zenith
AAA, the Excluder AAA endoprosthesis (WL Gore & Asso-
ciates, CA, USA) and Powerlink system (Endologix, CA,
USA) have been approved for insurance reimbursement. In
Japan, when new medical material goes through the
process of regulatory approval prior to being introduced to
the market, its usage results and utility are evaluated
scientifically from clinical results and other tests con-
ducted inside and outside Japan to ensure its safety and
effectiveness. However, regulatory approval is given for
medical materials and new technologies themselves; this
does not guarantee the skills of the doctor using them.
Therefore, the treatment results for a new medical
material in its early stages of use are greatly affected by
the skill level of the doctors using it.2,3 In daily clinical
practice, there is a learning curve in which patients are
often seen to be disadvantaged. When stent-graft systems
were introduced, 10 societies related to endovascular
treatment co-operated in formulating stent-grafting
practice standards and establishing the Japanese
Committee for Stentgraft Management (JACSM) as an
administrative body, with the aim of eliminating this
learning curve, improving safety and ensuring that use of
the systems spreads appropriately. JACSM screens and
approves practising institutions, practising surgeons, and
supervising surgeons, and conducts follow-up surveys of all
patients. In this article, we explain the practice stan-
dards, discuss the results of the follow-up surveys and
investigate the validity of JACSM.
Subjects and methods
Japanese Committee for Stentgraft Management
(http://wwww.stentgraft.jp/)
The Japanese Society for Vascular Surgery set up a practice
standard management committee as a directors’ advisory
body prior to the regulatory approval of stent grafts. With
reference to the guidelines of the Endovascular
Committee2 in the United States and the protocols of
multicentre clinical trials of the Zenith AAA endovascular
graft and Powerlink system in Japan, the committee
developed tentative practice standards for practising
institutions, practising surgeons and supervising surgeons.
Later, following a request for co-operation from the
Ministry of Health, Labor and Welfare, JACSM was estab-
lished in December 2006, comprising 10 societies (Table 1)
related to endovascular treatment. In June 2007, screening
was begun based on the practice standards.
Stent grafting practice standards
The practice standards consist of respective standards for
practising institutions, practising surgeons and supervising
surgeons, as well as supplemental notes. JACSM conducts
screening and approval based on application documents
(Table 2).Institutions
To deal with complications in the perioperative period, it is
necessary for an institution to have staff members who can
perform emergency aortic surgery; and vascular surgery
and endovascular treatment must be regularly performed
at the institution. In addition, treatment must be per-
formed in an operating room or angiography room equipped
with accurate X-ray equipment.
Practising surgeons
Practising surgeons must understand the pathology of AAAs
and be well versed in their treatment and patient
management. They must also have completed a training
programme consisting of classroom lectures with hands-on
training, case study and observation as a foundation for
endovascular treatment. After training, a practising
surgeon must have successfully treated two cases under
a supervising surgeon. Then, even when the surgeon can
perform the procedure independently, it is advised that he
or she receive guidance from a supervising surgeon until
sufficient diagnostic imaging ability and skills have been
acquired.
Supervising surgeons
Adequate knowledge, experience and skills are required
when supervising the performance of the procedure. The
ability to judge indications based on the characteristics of
stent grafting is of particular importance. Proper response
to complications is something that is learned through
repeated experience, and the number of experiences
stipulated in the practice standards must be regarded as no
more than a necessary minimum.
Supplemental note
Even after a surgeon is certified as a practising surgeon, it is
recommended that he or she request an opinion on the
indication and obtain the viewpoint of a supervising
surgeon. Practising surgeons are obligated to conduct
follow-up observations on all patients and report to JACSM.
Results
Examining results
There were 298 certified institutions as of June 2009;
however, it is unclear whether all of these institutions had
a practising surgeon on staff and whether EVAR was
Table 2 Practice Standards for Stent Grafting for Abdominal Aortic Aneurysms.
Standards for institutions
Equipment and personnel: a DSA apparatus must be installed in an operating room or an angiography room.
The institution must have a system that facilitates macrovascular surgery (see Note 1).
Surgical performance (see Note 2): at least 30 cases of vascular surgery or endovascular treatment,
including at least 10 cases of surgery or treatment for abdominal aortic aneurysm, must be performed per year.
Cooperation of surgeons: full-time surgeons with experience in at least three cases of surgery for ruptured abdominal aortic
aneurysms must be immediately available (surgeons include cardiovascular surgeons and surgeons at institutions where
cardiovascular surgeons are on staff).
Standards for practicing surgeons
Training obligation: must have completed a training program in the use of the type of stent graft to be used.
Basic experience: must have experience in at least 20 cases of endovascular treatment of the iliac artery.
Must have experience in at least 10 cases treating abdominal aortic aneurysms or iliac artery aneurysms
(surgery or stent graft implantation) as a practicing surgeon or assistant surgeon.
Experience: must have succeeded in implanting the type of stent graft to be used in at least two cases as a practicing
surgeon under the supervision of a supervising surgeon.
Standards for supervising surgeons
Performance: must have experience in at least 30 cases of stent graft implantation
(including implantation of handmade stents) as a practicing surgeon or first assistant surgeon.
Training obligation: must have completed a training program in the use of the type of stent graft to be used.
Experience: must have experience in at least 10 cases of surgery using the relevant stent graft as a practicing surgeon.
For those who have a certificate as a supervising surgeon in the use of other types of equipment, the requirement
is experience in at least five cases.
Academy qualifications: must be qualified as one of the followingda physician certified by the Japanese Society of
Interventional Cardiology or the Japan Association of Cardiovascular Catheterization Therapeutics or a certified specialist,
specialist certified by the Japanese Society of Interventional Radiology (JSIR), cardiovascular surgeon, or surgeon
at institutions where cardiovascular surgeons are on staff and certified by the JSIR.
Supplemental note
Determination of indication: seek the advice of a supervising surgeon on the determination of indication based
on imaging and selection of devices for the first 10 cases.
Imaging: diagnosis must be made based on CT images (3 mm or less slice thickness).
Investigation system (see Note 3): the institution must conduct follow-up investigations.
Information disclosure: the Stent Grafting Practice Standards Management Committee shall analyze data from follow-up
investigations and disclose the results of the analysis when necessary.
Note 1: the system referred to here includes the participation of anesthesiologists, nurses, and clinical engineers.
Note 2: surgical performance is the measure of whether the institution regularly performs vascular surgery and/or
endovascular treatment.
Note 3: the investigation system refers to a system that facilitates the cooperative management of safety and the
investigation of efficacy.
Practice Standards for EVAR in Japan S7performed regularly. Based on patient registration, it was
judged that EVAR was regularly performed at 150 institu-
tions. There were 493 certified practising surgeons. The
breakdown was 378 (76.7%) general and cardiovascular
surgeons, 75 (15.2%) radiologists and 40 (8.1%) cardiolo-
gists. There were 177 certified supervising surgeons. A total
of 3089 cases/150 hospitals were registered.4
Follow-up surveys
Practising institutions are obligated to report treatment
results for individual cases in a case-registry system via the
Internet. The present study analysed 1729 cases registered
in the 2 years from July 2006 to June 2008, following
approval of commercial stent grafts. During the same
period, among the number of applications for corporate
stents nationwide, EVAR was performed in 1897 cases.
Thus, the patient registration rate was 91%. The subjects
included 1570 of these patients for whom all data untilhospital discharge were recorded (input rate 83%).
The patients included 1379 males and 191 females, with
a mean age of 75.5 7.7 years (range, 45e96 years). The
mean aneurysm diameter was 51.9 10.2 mm (range,
25e120 mm) (Table 3). Surgery results included hospital
death in six cases (0.4%), the cause of which was acute
myocardial infarction in two cases and pneumonia, thoracic
aortic aneurysm rupture, multiple organ failure from
multiple embolism and ischaemic enteritis from superior
mesenteric arterial embolism in one case each. Endoleaks
were type I in 12 cases (0.8%), type II in 180 cases (9.6%),
type III in nine cases (0.6%), type IV in two cases (0.1%) and
unclear in five cases (0.3%). There were no cases of
migration at the time of discharge (Table 4).
Discussion
The Zenith AAA endovascular graft commercial stent graft
for the AAA received regulatory approval in Japan in July
Table 3 Preoperative characteristics of 1570 cases
undergoing EVAR.
Gender Male/Female 1379/191
Age Mean SD 75.5 7.7
(45e96)
Diagnosis Abdominal aortic
aneurysm
1552
Iliac aneurysm 16
Dissection 2
Etiology True 1517
Pseudo 27
Inflammatory 12
Dissection 11
Others 3
Co-morbidities Hypertension 1020
Coronary arterial disease 488
Respiratory disorder 398
Cerebral infurction 269
Renal dysfunctiona 255
Diabetes 199
Hostile abdomen 352
Image
measurement
Aneurysmal diameter (mm) 51.9 10.2
(25e120)
Proximal neck diameter (mm) 21.7 2.9
Proximal neck length (mm) 30.4 13.7
a Creatinine values of 1.2 mg/dl were taken to indicate
renal dysfunction.
Table 4 Postoperative complications at the time of
discharge.
Adverse event Hospital mortality 6 (0.4%)
Stenosis or obstruction
of stentgraft
9 (0.6%)
Stenosis or obstruction
of iliac artery
3 (0.2%)
Arterial injury 5 (0.3%)
Thromboembolism 17 (1.1%)
Infectious disease 4 (0.3%)
Renal dysfunctiona 40 (2.6%)
Paraparesis 1 (0.1%)
Wound complication 10 (0.6%)
Rupture 0
Others 14 (0.9%)
Stentgraft related
complication
Type I 12 (0.8%)
Proximal 7
Distal 4
Unknown 1
Type II 180 (9.6%)
Type III 9 (0.6%)
Type IV 2 (0.1%)
Unknown 5 (0.3%)
Migration 0
a Cases of worsening creatinine levels or dialysis were taken
to indicate renal dysfunction.
S8 Y. Obitsu et al.2006, and from April 2007 was authorised as a medical
material reimbursed by health insurance. To date, three
commercial stent-graft systems have been approved for use
in Japan. According to the annual statistics of the Japanese
Society for Vascular Surgery, 6105 AAA surgeries were per-
formed in 2006, of which 95% were artificial vessel
replacements and only 2.9% were EVAR. In 2007, however,
EVAR was performed in 736 of 6804 cases (10.8%).5 From the
number of cases registered with the JACSM, EVAR is esti-
mated to have accounted for 30% in 2008 and is therefore
considered to be spreading as a standard treatment for
AAA. In Japan, which was late to introduce EVAR, approval
for commercial stent grafts was finally obtained 10 years
later than in the European Union and 7 years later than
approval by the Food and Drug Administration (FDA) in the
United States. While this was a great loss for patients who
did not have the opportunity to receive the treatment until
then, when EVAR was first introduced in Japan, patients
were fortunate to be able to undergo EVAR with highly
sophisticated third-generation stent grafts whose safety
had already been established. When introducing this
procedure clinically, world-class treatment results are
required, for which a policy to minimise the learning curve
seen in the early period of use of new medical materials is
needed. It was against this background that JACSM was
established with the purpose of ensuring the safe and
appropriate reach of EVAR.
In the 2.5 years since the establishment of JACSM, 298
institutions have fulfilled the practice standards for stent
grafts, the number of practising surgeons has grown to 493
and the number of supervising surgeons to 177. There were3089 registered patients up to June 2009. The hospital
mortality rate of 1570 patients analysed in the present
follow-up study was low (0.4%) and compares favourably
with the results of the EVAR 1 trial (1.7%),6 the DREAM trial
(1.2%)7 and a US Medicare survey (1.2%).8 This is thought to
be the result of vascular surgeons and radiologists with
a high level of skill generally complying with indication
standards and indicates the effectiveness of the present
system established with the initiative of the academic
society. In a comparison of EVAR and artificial vessel
replacement, of the 6105 cases of AAA surgery performed in
2006 according to an annual survey of the Japanese Society
for Vascular Surgery,5 the hospital mortality rate in 5383
cases of elective surgery (excluding 722 cases of rupture)
was 0.98%. The mortality rate for EVAR was significantly
lower (Fisher’s exact test: p< 0.05), and results similar to
EVAR1 and DREAM were obtained. In the present survey, the
number of patients with complete data input was some-
what insufficient, so that there may be problems with
statistical analysis; however, valuable information was
thought to have been obtained for understanding the status
of EVAR in Japan. In the future, it will be important to
gather and analyse thorough follow-up information and to
share information by publicising the results of surveys and
analyses of medium- and long-term results. We also plan to
revise the practice standards as needed, based on future
results.
Conclusion
The early results following the introduction of stent grafts
in Japan were generally good. The procedure spread safely
Practice Standards for EVAR in Japan S9without the learning curve seen in the initial stages
following introduction of new medical materials, indicating
that the practice standards were appropriate.
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